Akèy › Nefrit Lupus › Pennsylvania
Etid klinik pou Nefrit Lupus nan Pennsylvania
7 etid pou Nefrit Lupus ap chèche patisipan nan sit nan Pennsylvania.
Vil nan Pennsylvania
Tèks ofisyèl etid la (Anglè)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Temple University, Philadelphia
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
- Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 1/2
Laj 10 a 29 · Tout sèks · Mizajou Sep 24, 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05201469RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Rheumatic Disease Associates, Ltd., Willow Grove
Ap rekriteFaz 4
Laj 18 a 75 · Tout sèks · Mizajou Aug 3, 2026 · NCT07611214A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.